ONC-392 is under clinical development by OncoC4 and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect ONC-392’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 23 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ONC-392 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
ONC-392 is under development for the treatment of metastatic solid tumors like malignant melanoma, renal cell carcinoma, hepatocellular carcinoma, pancreatic cancer, triple negative breast cancer, non-small cell lung cancer, head and neck carcinoma, gastric carcinoma, ovarian carcinoma, cervical cancer, colorectal cancer, sarcoma, peritoneal cancer, fallopian tube cancer, adenoid cystic carcinoma, esophageal cancer, anal canal cancer and unspecified indication. The drug candidate is a monoclonal antibody. It is administered through intravenous route. It acts by targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
It was also under development for the treatment of Merkel cell carcinoma.
OncoC4 is a biopharmaceutical company, provides oncology-related services. It is headquartered in Maryland, the US.
Quick View ONC-392 LOA Data
|Highest Development Stage|